Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full Proposal)
Funding Amounts: Up to $3,000,000 total for up to 3 years; budget varies by project scope.
Summary: Supports clinical trials to advance therapies specifically targeting cardiovascular disease in individuals with type 1 diabetes.
Key Information: LOI approval is required before full proposal submission; industry and academic collaborations are encouraged.